Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: lactose monohydrate; crospovidone; sucrose; docusate sodium; hypromellose; sodium lauryl sulfate; silicified microcrystalline cellulose; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; xanthan gum; polyvinyl alcohol; quinoline yellow aluminium lake; soy phosphatidylserine-enriched soy lecithin powder; indigo carmine aluminium lake - fenofibrate is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cetirizine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000; sodium citrate dihydrate - seasonal allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) in adults and children aged 6 years and over. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing and redness of the eyes. ,perennial allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children aged 6 years and over. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing. ,chronic idiopathic urticaria: cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children aged 6 years and over. it significantly reduces the occurrence, severity and duration of hives and markedly reduces pruritus. ,as with other antihistamines, patients should be advised to seek medical advice about the possibility that their urticaria is associated with ingestion of certain foods.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - montelukast sodium, quantity: 10.38 mg (equivalent: montelukast, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; povidone; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400; indigo carmine aluminium lake - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; maize starch; titanium dioxide; hypromellose; macrogol 6000 - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).